Antiretroviral-Free HIV-1 Remission and Viral Rebound After Allogeneic Stem Cell Transplantation Report of 2 Cases

被引:345
作者
Henrich, Timothy J.
Hanhauser, Emily
Marty, Francisco M.
Sirignano, Michael N.
Keating, Sheila
Lee, Tzong-Hae
Robles, Yvonne P.
Davis, Benjamin T.
Li, Jonathan Z.
Heisey, Andrea
Hill, Alison L.
Busch, Michael P.
Armand, Philippe
Soiffer, Robert J.
Altfeld, Marcus
Kuritzkes, Daniel R.
机构
[1] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Leibniz Inst Expt Virol, Heinrich Pette Inst, Hamburg, Germany
[4] Blood Syst Res Inst, San Francisco, CA 94118 USA
[5] Univ Calif San Francisco, San Francisco, CA 94143 USA
[6] MIT, Ragon Inst Massachusetts Gen Hosp, Cambridge, MA 02139 USA
[7] Harvard Univ, Cambridge, MA 02139 USA
基金
比尔及梅琳达.盖茨基金会; 美国国家卫生研究院;
关键词
BONE-MARROW-TRANSPLANTATION; STRUCTURED TREATMENT INTERRUPTIONS; VIRUS TYPE-1 INFECTION; POSITIVE PATIENTS; PCR ASSAY; THERAPY; VIREMIA; RNA; PLASMA; BLOOD;
D O I
10.7326/M14-1027
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: It is unknown whether the reduction in HIV-1 reservoirs seen after allogeneic hematopoietic stem cell transplantation (HSCT) with susceptible donor cells is sufficient to achieve sustained HIV-1 remission. Objective: To characterize HIV-1 reservoirs in blood and tissues and perform analytic antiretroviral treatment interruptions to determine the potential for allogeneic HSCT to lead to sustained, antiretroviral-free HIV-1 remission. Design: Case report with characterization of HIV-1 reservoirs and immunity before and after antiretroviral interruption. Setting: Tertiary care center. Patients: Two men with HIV with undetectable HIV-1 after allogeneic HSCT for hematologic tumors. Measurements: Quantification of HIV-1 in various tissues after HSCT and the duration of antiretroviral-free HIV-1 remission after treatment interruption. Results: No HIV-1 was detected from peripheral blood or rectal mucosa before analytic treatment interruption. Plasma HIV-1 RNA and cell-associated HIV-1 DNA remained undetectable until 12 and 32 weeks after antiretroviral cessation. Both patients experienced rebound viremia within 2 weeks of the most recent negative viral load measurement and developed symptoms consistent with the acute retroviral syndrome. One patient developed new efavirenz resistance after reinitiation of antiretroviral therapy. Reinitiation of active therapy led to viral decay and resolution of symptoms in both patients. Limitation: The study involved only 2 patients. Conclusion: Allogeneic HSCT may lead to loss of detectable HIV-1 from blood and gut tissue and variable periods of antiretroviral-free HIV-1 remission, but viral rebound can occur despite a minimum 3-log10 reduction in reservoir size. Long-lived tissue reservoirs may have contributed to viral persistence. The definition of the nature and half-life of such reservoirs is essential to achieve durable antiretroviral-free HIV-1 remission.
引用
收藏
页码:319 / +
页数:10
相关论文
共 39 条
  • [1] Evidence for the cure of HIV infection by CCR5Δ32/Δ32 stem cell transplantation
    Allers, Kristina
    Huetter, Gero
    Hofmann, Joerg
    Loddenkemper, Christoph
    Rieger, Kathrin
    Thiel, Eckhard
    Schneider, Thomas
    [J]. BLOOD, 2011, 117 (10) : 2791 - 2799
  • [2] Identification of dominant optimal HLA-B60-and HLA-B61-restricted cytotoxic T-lymphocyte (CTL) epitopes: Rapid characterization of CTL responses by enzyme-linked immunospot assay
    Altfeld, MA
    Trocha, A
    Eldridge, RL
    Rosenberg, ES
    Phillips, MN
    Addo, MM
    Sekaly, RP
    Kalams, SA
    Burchett, SA
    McIntosh, K
    Walker, BD
    Goulder, PJR
    [J]. JOURNAL OF VIROLOGY, 2000, 74 (18) : 8541 - 8549
  • [3] Failure of bone marrow transolantation to eradicate HIV reservoir desoite efficient HAART
    Avettand-Fenoel, Veronique
    Mahlaoui, Nizar
    Chaix, Marie-Laure
    Milliancourt, Catherine
    Burgard, Marianne
    Cavazzana-Calvo, Marina
    Rouzioux, Christine
    Blanche, Stephane
    [J]. AIDS, 2007, 21 (06) : 776 - 777
  • [4] Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication
    Chun, Tae-Wook
    Justement, J. Shawn
    Murray, Danielle
    Hallahan, Claire W.
    Maenza, Janine
    Collier, Ann C.
    Sheth, Prameet M.
    Kaul, Rupert
    Ostrowski, Mario
    Moir, Susan
    Kovacs, Colin
    Fauci, Anthony S.
    [J]. AIDS, 2010, 24 (18) : 2803 - 2808
  • [5] Quantification of latent tissue reservoirs and total body viral load in HIV-1 Infection
    Chun, TW
    Carruth, L
    Finzi, D
    Shen, XF
    DiGiuseppe, JA
    Taylor, H
    Hermankova, M
    Chadwick, K
    Margolick, J
    Quinn, TC
    Kuo, YH
    Brookmeyer, R
    Zeiger, MA
    BarditchCrovo, P
    Siliciano, RF
    [J]. NATURE, 1997, 387 (6629) : 183 - 188
  • [6] CONTU L, 1993, BONE MARROW TRANSPL, V12, P669
  • [7] TRANSIENT HIGH-LEVELS OF VIREMIA IN PATIENTS WITH PRIMARY HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION
    DAAR, ES
    MOUDGIL, T
    MEYER, RD
    HO, DD
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (14) : 961 - 964
  • [8] Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy
    Dinoso, J. B.
    Kim, S. Y.
    Wiegand, A. M.
    Palmer, S. E.
    Gange, S. J.
    Cranmer, L.
    O'Shea, A.
    Callender, M.
    Spivak, A.
    Brennan, T.
    Kearney, M. F.
    Proschan, M. A.
    Mican, J. M.
    Rehm, C. A.
    Coffin, J. M.
    Mellors, J. W.
    Siliciano, R. F.
    Maldarelli, F.
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (23) : 9403 - 9408
  • [9] Detection of Recent HIV-1 Infection Using a New Limiting-Antigen Avidity Assay: Potential for HIV-1 Incidence Estimates and Avidity Maturation Studies
    Duong, Yen T.
    Qiu, Maofeng
    De, Anindya K.
    Jackson, Keisha
    Dobbs, Trudy
    Kim, Andrea A.
    Nkengasong, John N.
    Parekh, Bharat S.
    [J]. PLOS ONE, 2012, 7 (03):
  • [10] El-Sadr WM, 2006, NEW ENGL J MED, V355, P2283, DOI 10.1056/NEJMoa062360